Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2501-2510 Newer>

The Motley Fool November 11, 2005 Stephen D. Simpson	Axcan Not in the Ash Can The base business of this Canadian specialty pharmaceutical won't grow quickly, but cash flow and the potential of the new ITAX drug could still move the shares.
BusinessWeek November 21, 2005 Gene G. Marcial	Salix Pharmaceuticals: What The Gut Tells You The small fry in gastrointestinal drugs is a pure play in that growing market.
The Motley Fool November 10, 2005 W.D. Crotty	Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%.
The Motley Fool November 10, 2005 Stephen D. Simpson	Hospitable Treatment for Hospira Solid margins fuel strong earnings at the hybrid generics - medical distributor. Buying this stock wisely may be the key to good long-term returns.
The Motley Fool November 9, 2005 W.D. Crotty	McKesson Fattens Its Margins The pharma distributor turns in an outstanding second quarter. Because McKesson is a broadly based supplier, it avoids the roller-coaster impact that specific drug successes and failures have on drug-developer stocks.
The Motley Fool November 9, 2005 Stephen D. Simpson	Greatbatch Keeps Growth Pumping Demand for implantable medical electronics keeps this battery and component maker humming. Investors new to this stock and/or medical technology in general will need to exercise some patience.
The Motley Fool November 9, 2005 Brian Gorman	Caremark's Room to Grow Fickle investors may fret about near-term growth, but the pharmacy benefit manager is prepared for the long haul. Investors looking for a long-term holding may want to mark a place in their portfolio for this company.
The Motley Fool November 8, 2005 Rich Smith	ViaCell Looks Healthier The cord blood collector reports narrowing losses. Investors, take note.
The Motley Fool November 8, 2005 Stephen D. Simpson	Teva Is No Generic Generics Firm Although 2005 wasn't a great year for generics on the whole, 2006 is shaping up to be pretty interesting for Teva. Is it time to buy these shares?
BusinessWeek November 14, 2005 Bruce Einhorn	Listen: The Sound Of Hope Cochlear implants could be a boon for the deaf - and a booming business.
<Older 2501-2510 Newer> Return to current articles.